BIOLARGO, INC.|5Feb 3, 2:53 PM ET

DARGAN CHARLES K 5

5 · BIOLARGO, INC. · Filed Feb 3, 2026

Form 5

Period: 2025-12-31

Chief Financial Officer

Transactions

Award
Option to Purchase Common Stock
[F2][F1]
2025-02-01+300,000→ 4,925,786 total
Exercise: $0.25From: 2025-03-01Exp: 2035-02-01→ Common Stock (300,000 underlying)
Other
Option to Purchase Common Stock
[F3]
2025-09-30$0.57/sh−300,000$171,000→ 4,625,786 total
Exercise: $0.57From: 2015-10-31Exp: 2025-09-30→ Common Stock (300,000 underlying)
Award
Option to Purchase Common Stock
[F4]
2025-09-30+1,005,882→ 5,631,668 total
Exercise: $0.17From: 2025-09-30Exp: 2035-09-30→ Common Stock (300,000 underlying)

Holdings

Option to Purchase Common Stock
[F5][F6][F7][F8]
→ Common Stock (0 underlying)
5,631,668

Footnotes (8)

[F1]The Option vests in equal monthly installments of 25,000 shares, so long as the Agreement between Reporting Person and Issuer remains in force and effect.
[F2]This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2025, through January 31, 2026.
[F3]The derivative security expired unexercised.
[F4]This Option was granted to Reporting Person to replace an option to purchase 300,000 shares that expired September 30, 2025 to compensate Reporting Person for services to the Issuer and had expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
[F5]Exercise prices vary.
[F6]All options may be exercised (are fully vested) as of the date of this Report.
[F7]Expiration dates vary.
[F8]Reflects total beneficial ownership by Reporting Person of Options to Purchase Common Stock of the Issuer as of the end of Issuer's most recent fiscal year (December 31, 2025).

Signature

/s/ John R. Browning, attorney-in-fact|2026-02-03

Documents

2 files